Interleukin-6inhibitor

Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. ... Hence, anti-IL6 ...

由 GR Burmester 著作 · 被引用 1 次 — Interleukin (IL) 6 is a potent proinflammatory mediator that is important in immune defense and in immune-mediated disease.

由 T Koga 著作 · 2022 · 被引用 9 次 — IL-6 is a potent inducer of serum amyloid A (SAA), which contributes to a positive feedback loop in inflammasomes by acting as a ligand. The ...

Interleukin (IL)-6 is a pleiotropic, proinflammatory cytokine produced by a variety of cell types, including lymphocytes, monocytes, and fibroblasts.

由 L Gandini 著作 · 2023 · 被引用 4 次 — In March 2020, tocilizumab, an interleukin (IL)-6 inhibitor, was approved for the treatment of Coronavirus Disease 2019 acute respiratory ...

由 S Hennigan 著作 · 2008 · 被引用 185 次 — Inhibitors of IL-6 were successful in animal models of autoimmune disease paving the way for subsequent studies in humans. The greatest experience to date has ...

2020年9月9日 — The currently approved IL-6 receptor antagonists' tocilizumab and sarilumab can significantly improve in the clinical manifestations of RA.

由 EH Choy 著作 · 2020 · 被引用 450 次 — Pharmacological inhibitors of IL-6 signalling prevent IL-6 from binding to IL-6R by targeting either the cytokine itself or the receptor. b | In ...

2021年7月6日 — Interleukin-6 blocking drugs – tocilizumab and sarilumab – act to suppress this overreaction. The prospective and living network meta-analyses ...

2022年6月7日 — 白血球介素-6 (Interleukin-6, IL-6) 是一種稱為細胞激素的蛋白質，有助於調節身體的免疫系統。其中IL-6 會引起發炎，幫助身體識別和抵抗感染，進而抵禦 ...